Refractory Chronic Cough Improvement Via NAL ER (RIVER)
Status:
Recruiting
Trial end date:
2024-10-01
Target enrollment:
Participant gender:
Summary
A 2-period crossover study for the treatment of cough in patients with Refractory Chronic
Cough via Nalbuphine ER (NAL ER). Each period will last 21 days and are separated by 21 days.
Subjects will be randomized in Treatment Period 1 to either NAL ER or matching placebo and
evaluated for 21 days. After completion of the first phase, subjects who received NAL ER will
crossover to placebo and subjects who received placebo will crossover to NAL ER to complete
Treatment Period 2.